CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $8.53B, above the global median of $1.18B
- PositionProfit margin is 55.2%, higher than 95% of its Biotechnology peers (median -32.5%)
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
8.53BUSDvs all stocks (USD)
Trailing P/E
20.12xvs Biotechnology peers
Revenue (TTM)
799.54MUSDvs all stocks (USD)
Profit Margin
55.22%vs Biotechnology peers
Beta
1.67xvs all stocks
52-Week Change
84.93%vs all stocks
Market Capitalization
8.53BUSDvs all stocks (USD)
Enterprise Value
8.11BUSDvs all stocks (USD)
Trailing P/E
20.12xvs Biotechnology peers
Forward P/E
18.79xvs Biotechnology peers
PEG Ratio
-0.2730xvs Biotechnology peers
Price to Sales (TTM)
10.67xvs Biotechnology peers
Price to Book (MRQ)
13.54xvs Biotechnology peers
Enterprise to Revenue
10.14xvs Biotechnology peers
Enterprise to EBITDA
59.41xvs Biotechnology peers
Gross Margin
82.86%vs Biotechnology peers
Profit Margin
55.22%vs Biotechnology peers
Operating Margin
9.02%vs Biotechnology peers
Return on Assets (TTM)
7.28%vs Biotechnology peers
Return on Equity (TTM)
100.28%vs Biotechnology peers
Revenue (TTM)
799.54MUSDvs all stocks (USD)
Revenue per Share (TTM)
5.61USDUpdated Aug 28, 2026Quarterly Revenue Growth
70.30%vs Biotechnology peers
Gross Profit (TTM)
658.60MUSDvs all stocks (USD)
EBITDA (TTM)
148.55MUSDvs all stocks (USD)
Net Income (TTM)
441.49MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-72.40%vs Biotechnology peers
Operating Cash Flow (TTM)
17.88MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
59.13MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
616.29MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
100.71MUSDFY2025 · Dec 31, 2025Gross Profit
515.57MUSDFY2025 · Dec 31, 2025Operating Income
123.32MUSDvs all stocks (USD)
Pre-tax Income
107.39MUSDFY2025 · Dec 31, 2025Income Tax Expense
-339.79MUSDFY2025 · Dec 31, 2025Net Income
447.18MUSDFY2025 · Dec 31, 2025EBIT
134.12MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
134.36MUSDFY2025 · Dec 31, 2025Research & Development
160.22MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
232.03MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
26.73MUSDFY2025 · Dec 31, 2025EPS (Basic)
3.10USDFY2025 · Dec 31, 2025EPS (Diluted)
2.77USDFY2025 · Dec 31, 2025Basic Shares Outstanding
144.32MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
144.32MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
447.18MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-83.33MUSDFY2025 · Dec 31, 2025Free Cash Flow
-83.55MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
80.49MUSDFY2025 · Dec 31, 2025Income Tax Paid
7.88MUSDFY2025 · Dec 31, 2025Interest Paid
24.25MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
447.18MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
244.00KUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-348.00MUSDFY2025 · Dec 31, 2025Stock-based Compensation
64.67MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.99MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-176.44MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-73.97MUSDFY2025 · Dec 31, 2025Capital Expenditures
-214.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-223.49MUSDFY2025 · Dec 31, 2025Sale of Investments
237.50MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
13.80MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Common Stock Repurchase
-91.24MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-91.24MUSDFY2025 · Dec 31, 2025Shares Outstanding
153.08MSharesUpdated Aug 28, 2026Float Shares
135.24MSharesUpdated Aug 28, 2026Shares Short
30.11MSharesUpdated Aug 28, 2026Short Ratio
13.30daysvs all stocks
Short % of Shares Outstanding
28.43%vs all stocks
% Held by Insiders
7.47%vs all stocks
% Held by Institutions
74.15%vs all stocks
Total Cash (MRQ)
552.25MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.89USDUpdated Aug 28, 2026Total Debt (MRQ)
754.44MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.25xvs Biotechnology peers
Current Ratio (MRQ)
4.27xvs Biotechnology peers
Book Value per Share (MRQ)
4.11USDUpdated Aug 28, 2026Total Assets
1.06BUSDvs all stocks (USD)
Total Current Assets
630.76MUSDFY2025 · Dec 31, 2025Total Liabilities
415.23MUSDFY2025 · Dec 31, 2025Total Non-current Assets
432.49MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
261.47MUSDFY2025 · Dec 31, 2025Total Current Liabilities
153.76MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
79.15MUSDFY2025 · Dec 31, 2025Other Short-term Investments
62.82MUSDFY2025 · Dec 31, 2025Accounts Receivable
305.63MUSDFY2025 · Dec 31, 2025Inventory
125.59MUSDFY2025 · Dec 31, 2025Short-term Debt
1.04MUSDFY2025 · Dec 31, 2025Deferred Revenue
21.23MUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.12MUSDFY2025 · Dec 31, 2025Long-term Debt
252.67MUSDFY2025 · Dec 31, 2025Common Stock (Book)
159.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.08BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
648.02MUSDvs all stocks (USD)
Treasury Stock
100.23MUSDFY2025 · Dec 31, 202552-Week Low
26.76USDUpdated Aug 28, 202652-Week High
59.30USDUpdated Aug 28, 202652-Week Change
84.93%vs all stocks
Beta
1.67xvs all stocks
50-Day MA
53.32USDUpdated Aug 28, 2026200-Day MA
38.27USDUpdated Aug 28, 2026Avg 10-Day Volume
1.96MSharesUpdated Aug 28, 2026Avg 30-Day Volume
2.24MSharesUpdated Aug 28, 2026Diluted EPS (TTM)
2.77USDUpdated Aug 28, 2026Other Income / Expense
10.79MUSDFY2025 · Dec 31, 20256 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Where is this company structurally exposed?
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 55.2%, higher than 95% of its Biotechnology peers (median -32.5%)Significant
Profit margin: 0.55Industry median: -0.32Industry P95: 0.39Peers compared: 194
Return on equity is 100.3%, higher than 95% of its Biotechnology peers (median -23.6%)Significant
Return on equity: 1.00Industry median: -0.24Industry P95: 0.23Peers compared: 194
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 441,489,984Operating Cash Flow (USD, TTM): 17,876,000
Financial Health
Altman Z-Score 12.43: safe zoneNotable
Altman Z-Score: 12.43
High structural barrier to entryNotable
Barrier to Entry: 27.81
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $8.53B, above the global median of $1.18BNotable
Market cap (USD): 8,529,817,077Global Median: 1,179,398,897.704
Revenue is $799.54M, above the global median of $534.05MNotable
Revenue (USD): 799,536,000Global Median: 534,052,387.958
Levered free cash flow is $59.13M, above the global median of $19.19MNotable
Levered free cash flow (USD): 59,134,500Global Median: 19,189,974.917
Companies that share the same coordination system — how they create, deliver, or capture value.
Bruker Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
ImmunityBio, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Alkermes plc
Tier 1ProductionApproval-Gated PipelineRule
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. A Shares
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Spyre Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Crinetics Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Immunovant Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vaxcyte, Inc.
Tier 1ProductionApproval-Gated PipelineRule
ALK-Abello A/S
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Allist Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Minda Corporation Ltd.
5 interpretationsReceivables Heavy and GrowingRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
Shanghai Henlius Biotech, Inc.
5 interpretationsMinimal Tax and Interest DragReceivables Heavy and GrowingRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
argenx SE
5 interpretationsMinimal Tax and Interest DragRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated